Research brief / questions answered
Sermorelin FAQ
The most-asked sermorelin questions, each answered straight from the published record.
What is sermorelin?
Sermorelin is GHRH(1-29)NH2 (GRF(1-29)), an amidated synthetic 29-amino-acid peptide matching the active N-terminal fragment of growth hormone-releasing hormone. It is a pituitary GH secretagogue: it stimulates the body's own pulsatile growth-hormone release rather than supplying GH from outside [7][11].
What is sermorelin used for?
It was a formerly FDA-approved product (NDA 020443) for evaluation and treatment of growth hormone deficiency / short stature in children, withdrawn from the US market in 2008 for commercial reasons [4]. It has since been studied in adults for the aging GH/IGF-1 axis, sleep, cognition, and body composition [2][5].
Does sermorelin work?
In GH-deficient children it accelerated first-year height velocity from about 4.1 to roughly 7-8 cm/year [1]. In healthy older men, 14 days of subcutaneous GHRH(1-29) raised 24-hour GH and IGF-1 into the young-adult range [2]. Its best-evidenced effects are on the GH/IGF-1 axis itself.
How long does it take for sermorelin to work?
Acutely, a single dose elevates serum GH for roughly 3 hours despite the peptide's ~10-12 minute half-life [3]. IGF-1 changes accrue over days to weeks of repeated dosing [2]. So a GH bump is same-day; an IGF-1 shift is multi-week.
What are the side effects of sermorelin?
In trial data, reported effects were mild and transient: injection-site reactions more frequent than placebo, and in GH-deficient children given GHRH(1-29) at 30-60 mcg/kg/day, reversible GHRH antibodies appeared in nearly all patients with no serious side-effects [18][10]. See the sermorelin side effects page for the full readout.
Who should not use sermorelin?
Sermorelin is a research compound, not a self-administered medicine. Because GH and IGF-1 are mitogenic, chronically raising them is a recognized theoretical oncologic consideration for any GH-axis intervention, and GH secretagogues are prohibited in sport by WADA [5].
Is long-term sermorelin use safe?
Long-term tolerability data specifically for adult anti-aging use remain limited; an Annals of Internal Medicine editorial judged GH-secretagogue use for aging 'not yet ready for prime time' [5]. Short-term tolerability in controlled studies was favorable [18].
What is known beyond short-term studies?
Most controlled GHRH(1-29) studies ran weeks to months (14 days in older men, 6 months in children), so robust beyond-12-week adult tolerability data are genuinely sparse, which is why authorities caution against assuming long-term safety [2][18][5].
Can women take sermorelin?
GHRH(1-29) has been studied in both sexes — for example, GHRH-analog research enrolled aging men and women [17]. This is research context, not a recommendation to self-administer; the literature treats sermorelin as a GH-axis research compound, not a sex-specific intervention.
Can sermorelin or GHRH improve cognition in older adults?
In a randomized, double-blind, placebo-controlled trial of 152 older adults (66 with MCI), 20 weeks of a GHRH analog had a favorable effect on cognition (P=0.03), alongside a 117% IGF-1 rise and a 7.4% reduction in body fat [17]. The trial used the stabilized analog tesamorelin.
How does sermorelin compare to CJC-1295?
Both act at the GHRH receptor, but native GHRH(1-29) is short-lived; the D-Ala2 substitution and DAC technology behind CJC-1295 prolong half-life and reduce metabolic clearance [13], trading sermorelin's brief, physiologic pulse for sustained exposure.
Sermorelin vs ipamorelin: what is the difference?
Sermorelin is a GHRH analog acting on the GHRH receptor; ipamorelin is a growth-hormone-releasing peptide (GHRP) acting on the separate ghrelin/GHS receptor — a fundamentally different mechanism within the same GH-axis goal [7]. See the sermorelin vs ipamorelin page.
How does sermorelin differ from direct HGH injections?
Sermorelin acts upstream on the pituitary, preserving feedback through somatostatin and IGF-1 and the natural pulsatile GH pattern; an editorial argued this may be a more physiologic approach than recombinant GH for adult-onset GH insufficiency [4].
Will sermorelin raise my IGF-1 levels?
In study populations, yes: 14 days of subcutaneous GHRH(1-29) raised IGF-1 dose-dependently in older men, restoring it toward young-adult levels at the high dose [2], via GH-driven hepatic IGF-1 production.
Does sermorelin affect testosterone?
Sermorelin acts on the GH/IGF-1 axis, not the gonadal axis; in older men, subcutaneous GHRH(1-29) raised GH and IGF-1 [2]. The literature frames it around IGF-1 and body composition, not as a testosterone therapy.
Does sermorelin burn fat?
Pulsatile GH regulates lipolysis in fasting humans [6], and the stabilized GHRH analog tesamorelin reduced visceral fat in HIV-associated fat accumulation [9]; direct fat-loss evidence for sermorelin itself in healthy adults is limited.
Is sermorelin effective for weight loss?
Body-composition effects in the GHRH-analog literature come largely from tesamorelin in specific populations (visceral-fat reduction) [9], and anti-aging/body-composition marketing for sermorelin outpaces the rigorous evidence [5].
Does sermorelin build muscle?
GH/IGF-1-axis modulation is discussed as a candidate strategy against age-related muscle loss (sarcopenia) [15], but sermorelin raises GH/IGF-1 rather than directly demonstrating muscle hypertrophy in controlled human trials.
Does sermorelin actually help with sleep?
GHRH had sleep-promoting (slow-wave sleep) effects in normal men [12], but its sleep-endocrine effects depend on the time of administration [10] — which is why timing matters and reported effects can vary.
Why is it recommended to inject sermorelin at night?
GH is secreted in pulses concentrated during slow-wave sleep, and GHRH promotes slow-wave sleep [12]; the pediatric efficacy regimen used a bedtime subcutaneous dose [1], aligning administration with the body's natural nocturnal GH surge.
Does sermorelin affect the brain?
GHRH administration modulated brain GABA levels in mild cognitive impairment and healthy aging [16], a neurochemical correlate of the cognitive effects seen in GHRH-analog trials.